用于治疗注意力缺陷多动障碍的ω-3/ω-6脂肪酸：一项针对儿童和青少年的随机安慰剂对照试验
Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents.
作者信息
Johnson Mats, Ostlund Sven, Fransson Gunnar, Kadesjö Björn, Gillberg Christopher
机构信息
Department of Child and Adolescent Psychiatry, Göteborg University, Göteborg, Sweden.
出版信息
J Atten Disord. 2009 Mar;12(5):394-401. doi: 10.1177/1087054708316261. Epub 2008 Apr 30.
OBJECTIVE
The aim of the study was to assess omega 3/6 fatty acids (eye q) in attention deficit hyperactivity disorder (ADHD).
METHOD
The study included a randomized, 3-month, omega 3/6 placebo-controlled, one-way crossover trial with 75 children and adolescents (8-18 years), followed by 3 months with omega 3/6 for all. Investigator-rated ADHD Rating Scale-IV and Clinical Global Impression (CGI) scale were outcome measures.
RESULTS
A majority did not respond to omega 3/6 treatment. However, a subgroup of 26% responded with more than 25% reduction of ADHD symptoms and a drop of CGI scores to the near-normal range. After 6 months, 47% of all showed such improvement. Responders tended to have ADHD inattentive subtype and comorbid neurodevelopmental disorders.
CONCLUSION
A subgroup of children and adolescents with ADHD, characterized by inattention and associated neurodevelopmental disorders, treated with omega 3/6 fatty acids for 6 months responded with meaningful reduction of ADHD symptoms.
目的
本研究旨在评估ω-3/6脂肪酸（Eye Q）对注意力缺陷多动障碍（ADHD）的作用。
方法
该研究为一项随机、为期3个月的、ω-3/6脂肪酸与安慰剂对照的单向交叉试验，共纳入75名儿童和青少年（8至18岁），之后所有人均接受3个月的ω-3/6脂肪酸治疗。以研究者评定的ADHD评定量表-IV和临床总体印象（CGI）量表作为疗效指标。
结果
大多数人对ω-3/6脂肪酸治疗无反应。然而，26%的亚组患者ADHD症状减轻超过25%，CGI评分降至接近正常范围。6个月后，47%的患者有上述改善。有反应者往往为ADHD注意力不集中亚型且伴有共病神经发育障碍。
结论
以注意力不集中和相关神经发育障碍为特征的ADHD儿童和青少年亚组，接受ω-3/6脂肪酸治疗6个月后，ADHD症状得到显著减轻。
Zotero 插件